Cargando…
Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
Early response could be obtained in most patients with relapsed or refractory B cell lymphoblastic leukemia (R/R B-ALL) treated with chimeric antigen receptor T-cell (CAR-T) therapy, but relapse occurs in some patients. There is no consensus on treatment strategy post CAR-T cell therapy. In this ret...
Autores principales: | Chen, Wei, Ma, Yuhan, Shen, Ziyuan, Chen, Huimin, Ma, Ruixue, Yan, Dongmei, Shi, Ming, Wang, Xiangmin, Song, Xuguang, Sun, Cai, Cao, Jiang, Cheng, Hai, Zhu, Feng, Sun, Haiying, Li, Depeng, Li, Zhenyu, Zheng, Junnian, Xu, Kailin, Sang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586453/ https://www.ncbi.nlm.nih.gov/pubmed/34777367 http://dx.doi.org/10.3389/fimmu.2021.755549 |
Ejemplares similares
-
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021) -
The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018) -
Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021) -
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma
por: Zhang, Huanxin, et al.
Publicado: (2022) -
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)